Management

Per Andersson
Chief Executive Officer
Chief Executive Officer at Xspray Pharma since 2006
Born 1967
Per Andersson has been the CEO of Xspray Pharma AB since 2006. Per Andersson has extensive experience from the medical industry, especially within patent work and strategies. Previous positions include Science Director at Gyros AB and Scientist at GE Healthcare
Education: Ph.D. in Analytical Chemistry, Stockholm university
Other current activities:
Chairman of the board of Robotic Lawn Care Sweden AB and Xspray Pharma Futurum AB and deputy board member in Journeyman Stockholm AB
Previous assignments (recent 5 years): –
Holdings: 200,260 shares and 61,186 options of which 33,062 warrants and 28,124 employee stock options
Independent in relation to the larger shareholders but not in relation to the company

Kerstin Hasselgren
Chief Financial Officer
Chief Financial Officer at Xspray Pharma since 2019
Born 1961
Kerstin Hasselgren has broad experience from working in large public international companies as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca
Education: M.Sc. Business Administration, Stockholm School of Economics
Other current activities:
None
Previous assignments (the recent 5 years): None
Holdings in the Company: 5,500 shares and 92,288 options of which 69,788 warrants and 22,500 employee stock options
Independent in relation to major shareholders but not in relation to the Company

Anna-Karin Ekberg
Senior Vice President, Global Head Marketing & Sales
Senior Vice President, Global Head Marketing & Sales since March 2022
Born 1966
Anna-Karin Ekberg has more than 25 years of experience from various management positions in the pharma industry. Her experience reaches from Nordic to international/HQ global positions and from small biotech to big pharma. Anna-Karin launched Glivec.
She has previously held positions with Schering AG, Novartis, HRA Pharma, Ariad, Aprea, Norgine and Oncopeptides.
Education: Bachelor of science in Diagnostic Radiology and Nursing Science, Uppsala University, DIHM Business School, Stockholm
Other current activities:
CEO/owner TAKE-Life Science & Business partner AB and collaboration with STILLE AB – product STILLE-Ekberg Ergo Scissors
Previous assignments (the recent 5 years): Board member Picture my Life AB
Holdings in the Company: 25,311 options of which 8,437 warrants and 16,874 employee stock options
Independent in relation to major shareholders but not in relation to the Company

Andreas Konar
Senior Vice President Business Development
Senior Vice President Business Development at Xspray since 2010
Born 1949
Andreas Konar has 4 decades of experience from the pharmaceutical industry in R&D, clinical research, project management and business development. He has been VP R&D at Dumex and AL Pharma, responsible for the Drug Delivery Business Unit at LifeCycle Pharma, business development at Recordati and section manager at Astra Draco
Education:
Associate Professor in Organic Chemistry, University of Lund, Sweden
Ph.D. in Organic Chemistry, University of Lund, Sweden
M.Sc. in Chemical Engineering, Chalmers University of Technology, Gothenburg, Sweden
Other current activities:
Member of the Board of Ground Zero Pharmaceuticals, Irvine, CA, USA
Previous assignments (recent 5 years): None
Holdings in the Company: 73,555 shares, 13,500 warrants
Independent in relation to major shareholders but not in relation to the Company

Charlotta Liljebris
Senior Vice President Research and Development
Senior Vice President Research and Development at Xspray Pharma since 2018
Born 1964
Charlotta Liljebris has 30 years of experience from the pharmaceutical industry. She has been responsible for the project portfolio and business development at Orexo, VP R&D at Aprea with focus on oncology and worked in several leading positions within project management at Biovitrum.
Education:
Ph.D. in Medicinal Chemistry, Uppsala University, Sweden
M.Sc. in Chemistry, Uppsala University, Sweden
Other current activities:
Deputy board member in Liljebris Consulting AB
Previous assignments (the recent 5 years): Member of the Board in Recipharm OT Chemistry, Connect Uppsala and Sprint Bioscience
Holdings in the Company: 2,000 shares and 38,814 options of which 21,938 warrants and 16,876 employee stock options
Independent in relation to major shareholders but not in relation to the Company.

Thomas Walz
Chief Medical Officer
Chief Medical Officer at Xspray Pharma since September 2022
Born 1960
Thomas was previously the Head of Department of Oncology at Karolinska University Hospital and has extensive experience in from the pharmaceutical industry. He most recently joins from the position as the Nordic Medical Director of Oncology at GSK.
Education: Associate professor in Oncology at Linköping University and an MBA degree from Stockholm School of Economics
Other current activities:
None
Previous assignments (recent 5 years): None
Holdings: 25,311 options of which 8,437 warrants and 16,874 employee stock options
Independent in relation to the larger shareholders but not in relation to the company